ESMO 2022: SWOG S1801 Trial of Timing of Pembrolizumab in Resected Advanced Melanoma
Posted: 09/23/2022 | By: Justine Landin, PhD

Findings from SWOG S1801, a randomized phase II study of adjuvant vs neoadjuvant therapy with pembrolizumab, were presented by Patel et al at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA6).

Question 1 of 5

Which endpoint was found to be significantly higher following neoadjuvant therapy compared to adjuvant therapy?

Choose 1